MMP-9-IN-1
Based on 8 publication(s) in Google Scholar
MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs.
For research use only. We do not sell to patients.
- Purity: 99.82%
- CAS No.: 502887-71-0
- Formula: C16H17F2N3O3S
- Molecular Weight:369.39
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Differentiation Inducing Compound Library
HY-L038
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Targeted Diversity Library
HY-L099
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Pain-Related Compound Library
HY-L139
-
Protease Inhibitor Library
HY-L147
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
Publications Citing Use of MedChemExpress (MCE) MMP-9-IN-1
More- Nat Commun. 2024 Dec 3;15(1):10536. [Abstract]
- J Immunother Cancer. 2024 Jun 17;12(6):e008375. [Abstract]
- Cell Death Discov. 2024 Feb 14;10(1):77. [Abstract]
- Eur J Pharmacol. 2023 Sep 5:954:175858. [Abstract]
- J Cell Mol Med. 2020 Sep;24(18):10604-10614. [Abstract]
- Biol Reprod. 2025 Jan 17:ioaf012. [Abstract]
- Int J Morphol. 2023 Aug, 41(4):1152-1157.
- Saarland University. 2025.
Customer Validation & Images
-
WB
-
Cell Migration/Invasion Assay
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
In Vivo Efficacy Study
Biological Activity
|
MMP-9 |
MMP-9-IN-1 (compound 2; 100 μM; 14 hours) does not cause notable cytotoxicity[1].
MMP-9-IN-1 (compound 2; 10 μM) significantly inhibits cell proliferation of HT-1080 and MDA-MB-435 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:COS-1 monkey epithelial cell lines
-
Concentration:100 μM
-
Incubation Time:24 hours
-
Result:Treatment did not cause notable cytotoxicity.
-
Cell Line:HT-1080 and MDA-MB-435 cancer cells expressing endogenous MMP-9
-
Concentration:10 μM
-
Incubation Time:9 days
-
Result:Significant inhibition of cell proliferation.
MMP-9-IN-1 inhibits cancer cell metastasis in vivo[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor[1]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks,
-
Result:Resulted in a profound delay in tumor growth.
Inhibited cancer cell metastasis.
Chemical Information
-
CAS No. 502887-71-0
-
Appearance Solid
-
Molecular Weight 369.39
-
Formula C16H17F2N3O3S
-
Color White to off-white
-
SMILES
O=C(NC1=CC=C(OC(F)F)C=C1)CSC2=NC(CCC)=CC(N2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
CRL3Keap1 E3 ligase facilitates ubiquitin-mediated degradation of oncogenic SRX to suppress colorectal cancer progression. [Abstract]2024 Dec 3;15(1):10536. PMID: 39627198
MMP-9-IN-1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Dec 3;15(1):10536. [Abstract]
Transwell assays were employed to evaluate the migration and invasion abilities of Keap1-knockdown HCT116 cells treated with 40 μM MMP9 inhibitor MMP-9-IN-1 for 48 h (n = 5). The cells were harvested for western blotting analysis.
MMP-9-IN-1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Dec 3;15(1):10536. [Abstract]
Transwell assays were employed to evaluate the migration and invasion abilities of Keap1-knockdown HCT116 cells treated with 40 μM MMP9 inhibitor MMP-9-IN-1 for 48 h (n = 5). Representative images were captured. The scale bar was 200 μm.
-
J Immunother Cancer
EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion. [Abstract]2024 Jun 17;12(6):e008375. PMID: 38886114 -
Cell Death Discov
ROS/MMP-9 mediated CS degradation in BMSC inhibits citric acid metabolism participating in the dual regulation of bone remodelling. [Abstract]2024 Feb 14;10(1):77. PMID: 38355572
MMP-9-IN-1 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Feb 14;10(1):77. [Abstract]
Effect of MMP-9-IN-1 ( 0.1-10 µM; 24-72 h) on osteoblast proliferation.
MMP-9-IN-1 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Feb 14;10(1):77. [Abstract]
MMP-9-IN-1 (0.1-10 µM; 72 h) significantly inhibited MMP-9 activity in cells.
-
Eur J Pharmacol
2023 Sep 5:954:175858. PMID: 37356787
MMP-9-IN-1 purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2023 Sep 5:954:175858. [Abstract]
MMP-9-IN-1 (20 mg/kg; i.g.; once every other day for a total of 5 administrations) significantly increased mechanical allodynia to Von Frey filaments, prolonged the latency of thermal hyperalgesia, and reduced spontaneous pain behaviors in rats with bone cancer pain (BCP).
-
J Cell Mol Med
PDX regulates inflammatory cell infiltration via resident macrophage in LPS-induced lung injury. [Abstract]2020 Sep;24(18):10604-10614. PMID: 32735065 -
Biol Reprod
Collagen turnover during cervical remodeling involves both intracellular and extracellular collagen degradation pathways. [Abstract]2025 Jan 17:ioaf012. PMID: 39823285 -
-
Solvent & Solubility
DMSO : 66.67 mg/mL (180.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Dufour A, et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res. 2011 Jul 15;71(14):4977-88. [Content Brief]
[2]. Alford VM, Kamath A, Ren X, et al. Targeting the Hemopexin-like Domain of Latent Matrix Metalloproteinase-9 (proMMP-9) with a Small Molecule Inhibitor Prevents the Formation of Focal Adhesion Junctions. ACS Chem Biol. 2017;12(11):2788-2803. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7072 mL | 13.5358 mL | 27.0717 mL | 67.6791 mL |
| 5 mM | 0.5414 mL | 2.7072 mL | 5.4143 mL | 13.5358 mL | |
| 10 mM | 0.2707 mL | 1.3536 mL | 2.7072 mL | 6.7679 mL | |
| 15 mM | 0.1805 mL | 0.9024 mL | 1.8048 mL | 4.5119 mL | |
| 20 mM | 0.1354 mL | 0.6768 mL | 1.3536 mL | 3.3840 mL | |
| 25 mM | 0.1083 mL | 0.5414 mL | 1.0829 mL | 2.7072 mL | |
| 30 mM | 0.0902 mL | 0.4512 mL | 0.9024 mL | 2.2560 mL | |
| 40 mM | 0.0677 mL | 0.3384 mL | 0.6768 mL | 1.6920 mL | |
| 50 mM | 0.0541 mL | 0.2707 mL | 0.5414 mL | 1.3536 mL | |
| 60 mM | 0.0451 mL | 0.2256 mL | 0.4512 mL | 1.1280 mL | |
| 80 mM | 0.0338 mL | 0.1692 mL | 0.3384 mL | 0.8460 mL | |
| 100 mM | 0.0271 mL | 0.1354 mL | 0.2707 mL | 0.6768 mL |
MMP-9-IN-1 Related Classifications
HY-135232 Related Classifications
Powered by Bioz